argenx SE (FRA:1AE) Operating Margin %: 30.35% (As of Mar. 2026)


FRA:1AE argenx SE FRA:1AE
78 GF Score
Price €753.20
GF Value €1,204.08
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is argenx SE Operating Margin %?

argenx SE FRA:1AE -1.02% 78 Operating Margin % is 30.35% as of Mar. 2026. GuruFocus rates FRA:1AE with a GF Score™ of 78/100 and a GF Value™ of €1,204.08 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 945 Biotechnology companies, argenx SE ranks better than 92.59% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. argenx SE's Operating Income for the three months ended in Mar. 2026 was €341 Mil. argenx SE's Revenue for the three months ended in Mar. 2026 was €1,123 Mil. Therefore, argenx SE's Operating Margin % for the quarter that ended in Mar. 2026 was 30.35%.

The historical rank and industry rank for argenx SE's Operating Margin % or its related term are showing as below:

FRA:1AE' s Operating Margin % Range Over the Past 10 Years
Min: -1165.2   Med: -108.97   Max: 28.08
Current: 28.08


FRA:1AE's Operating Margin % is ranked better than
92.59% of 945 companies
in the Biotechnology industry
Industry Median: -86.89 vs FRA:1AE: 28.08

argenx SE's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

argenx SE's Operating Income for the three months ended in Mar. 2026 was €341 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was €1,125 Mil.


argenx SE  (FRA:1AE) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


argenx SE Operating Margin % Related Terms


argenx SE Operating Margin % Historical Data

* Premium members only.

The historical data trend for argenx SE's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

argenx SE Operating Margin % Chart

argenx SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -72.37 -176.25 -34.30 -0.81 25.39

argenx SE Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.59 21.72 31.05 27.92 30.35

FRA:1AE vs VRTX, REGN, ALNY: Operating Margin % Comparison

For the Biotechnology subindustry, argenx SE's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


argenx SE Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, argenx SE's Operating Margin % distribution charts can be found below:

* The bar in red indicates where argenx SE's Operating Margin % falls into.


FRA:1AE
78GF Score
argenx SE FRA:1AE
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

argenx SE Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

argenx SE's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=900.641 / 3547.074
=25.39 %

argenx SE's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=340.81 / 1122.77
=30.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 30.35% mean?
argenx SE (FRA:1AE) has a Operating Margin % of 30.35% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on argenx SE and its competitors. According to the industry distribution chart, argenx SE ranks #70 out of 945 companies in the Biotechnology industry, placing it in the top 7.4%.
Is argenx SE's Operating Margin % too high?
argenx SE's current Operating Margin % is 30.35%. Based on the distribution chart, argenx SE ranks #70 out of 945 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, argenx SE has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does argenx SE's Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, argenx SE ranks #70 out of 945 companies for Operating Margin %. This places argenx SE in the top 7% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on argenx SE and its competitors. argenx SE's current Operating Margin % is 30.35%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is argenx SE stock overvalued right now?
Based on GuruFocus' analysis, argenx SE (FRA:1AE) is currently considered Significantly Undervalued. The stock's GF Value™ is €1,204.08, compared to a current price of €753.20 — trading 37.4% below its estimated fair value. The current Operating Margin % is 30.35%. argenx SE's overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For argenx SE (FRA:1AE), the current Operating Margin % is 30.35% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is argenx SE (FRA:1AE) Overvalued in 2026?

Based on GuruFocus' analysis, argenx SE stock appears to be undervalued. The current stock price of €753.20 is trading 37.4% below its estimated GF Value™ of €1,204.08. GuruFocus considers argenx SE to be Significantly Undervalued.

Key valuation signals for FRA:1AE:

  • Operating Margin %: 30.35%
  • GF Value™: €1,204.08 vs. price of €753.20 (37.4% below fair value)
  • GF Score™: 78/100 with 5 warning signs

No single metric tells the full story. See the FRA:1AE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


argenx SE Business Description

Address Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
78GF Score

Get the complete analysis for FRA:1AE

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€753.20
Price
€1,204.08
GF Value